Présentation de l'entreprise
Genmab A/S operates as a biotechnology firm based in Denmark that specializes in the development and marketing of antibody-based products and product candidates designed for the treatment of cancer and various other diseases. The company functions within the Healthcare sector, specifically targeting the Biotechnology industry, where it focuses on creating innovative therapeutic solutions for serious medical conditions such as relapsed or refractory diffuse large B-cell lymphoma. This entity employs a workforce of 2,973 individuals and holds a market capitalization of $17.53 billion, while generating a trailing twelve-month revenue of $3.72 billion. These financial dimensions indicate that Genmab A/S is a substantial player within its niche, possessing a significant market valuation that reflects its established position in the antibody therapeutic space despite the inherent volatility of the biotechnology sector.
Santé financière
The company reported a trailing twelve-month revenue of $3.72 billion and a net income of $963.00 million, with an EBITDA of $1.29 billion, revealing a cost structure where operating expenses and taxes consume approximately 74.1% of the gross revenue before arriving at net profit. The firm maintains a free cash flow of $1.07 billion, which provides substantial financial flexibility to fund research and development initiatives, acquire assets, or manage capital expenditures without immediate reliance on external financing. Profitability analysis shows a gross margin of 93.6%, indicating high efficiency in production and supply chain costs typical of biotech manufacturing, an operating margin of 23.0% that demonstrates effective control over overhead and administrative expenses, and a profit margin of 25.9% that highlights the company's ability to convert a significant portion of sales into bottom-line earnings. On the liability side, Genmab A/S holds $1.72 billion in cash against $5.43 billion in total debt, resulting in a debt-to-equity ratio of 92.80, which suggests a leveraged balance sheet where interest obligations are substantial relative to equity capitalization. Liquidity is supported by a current ratio of 2.02, indicating that the company possesses more than double the current assets necessary to cover its short-term liabilities, thereby ensuring robust short-term solvency. Management effectiveness is further evidenced by a return on equity of 17.5% and a return on assets of 8.1%, metrics that demonstrate the company's ability to generate significant returns on the capital provided by shareholders and deployed across its asset base.
Évaluation de la valorisation
The stock carries a trailing twelve-month P/E ratio of 18.44 and a forward P/E of 16.06, implying that the market expects earnings growth sufficient to justify the lower forward multiple compared to the historical trailing multiple. The price-to-book ratio stands at 2.99, suggesting that the market values the company at nearly three times its net asset value, which reflects a premium assigned to its intangible assets, intellectual property, and future growth potential rather than just tangible book value. Alternative valuation metrics include a price-to-sales ratio of 4.71 and an EV/EBITDA of 4.23, figures that provide context for the company's valuation relative to its revenue generation and earnings power independent of share price fluctuations. Over the past year, the stock has traded between a 52-week low of $17.23 and a 52-week high of $35.43, with the current price point situated somewhere within this range, reflecting the recent volatility experienced by the security. The beta coefficient is recorded at 0.74, indicating that the stock exhibits lower price volatility than the broader market, moving less aggressively in response to general market shifts.
Growth & Income
Revenue growth stands at 3.0% year-over-year, while earnings growth has declined by -94.4% year-over-year, illustrating that earnings are contracting at a much faster rate than revenue, which points to a significant compression in net income despite stable top-line sales. The company does not distribute dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, indicating a strategy of reinvesting all available earnings back into operations and research rather than returning capital to shareholders. This absence of dividend payouts aligns with the company's lifecycle stage, where capital is prioritized for expansion and product development over income generation for investors. Overall, the growth and income profile is characterized by modest top-line expansion coupled with a sharp decline in profitability and no current income distribution, requiring investors to rely on potential capital appreciation rather than yield.